Scientists map bacteria in lung cancer patients to pave way for new treatments

NCT ID NCT03068663

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the bacteria living in the gut, lungs, and airways of 40 people with non-small cell lung cancer. Half receive surgery only, and half get chemotherapy before surgery. Researchers collect samples like blood, saliva, stool, and lung tissue to see how these bacteria change. The goal is to understand the bacteria better so future studies can test if probiotics help make cancer treatment work better or cause fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could lay the groundwork for future treatments that use probiotics or prebiotics to improve cancer therapy tolerance and effectiveness.

What could go wrong

This is a small, early exploratory study with only 40 participants, so results may not apply to all lung cancer patients. It does not test any treatment directly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Jean Perrin

    Clermont-Ferrand, Puy de dôme, 63003, France